Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts

International Journal of Oncology

Volumn 44, Issue 1, 2014, Pages 137-146

  Muñoz, Miguel ^a   Berger, Michael ^a,b   Rosso, Marisa ^a   Gonzalez Ortega, Ana ^a   Carranza, Andrés ^a   Covẽnas, Rafael ^c  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Antitumor target; Apoptosis; Aprepitant; Fosaprepitant; L 732,138; L 733,060; Neurokinin 1 receptor; Osteosarcoma; Substance P; Tumor cell lines; Xenograft

Indexed keywords

3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; 4',6 DIAMIDINO 2 PHENYLINDOLE; APREPITANT; CISPLATIN; DOXORUBICIN; FOSAPREPITANT; IFOSFAMIDE; MESSENGER RNA; MITOMYCIN; MW 53443; N ACETYLTRYPTOPHAN 3,5 BIS(TRIFLUOROMETHYL)BENZYL ESTER; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; SUBSTANCE P; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CELL DENSITY; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG CYTOTOXICITY; DRUG POTENTIATION; EMBRYO; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MITOSIS; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERAPY EFFECT; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADOLESCENT; ANIMALS; CHILD; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HETEROGRAFTS; HUMANS; MICE; MORPHOLINES; NEUROKININ-1 RECEPTOR ANTAGONISTS; OSTEOSARCOMA; RECEPTORS, NEUROKININ-1; RNA, MESSENGER;

EID: 84891949800     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2164     Document Type: Article

References (33)

1. Wittig JC, Bickels J, Priebat D, et al: Osteosarcoma: a multi-disciplinary approach to diagnosis and treatment. Am Fam Physician 65: 1123-1132, 2002.
2. Ritter J and Bielack SS: Osteosarcoma. Ann Oncol 21 (Suppl 7): vii320-vii325, 2010.
3. Muñoz M, Rosso M and Coveñas R: A new frontier in the treatment of cancer: NK-1 receptor antagonists. Curr Med Chem 17: 504-516, 2010.
4. Muñoz M, Rosso M and Coveñas R: The NK-1 receptor: a new target in cancer therapy. Curr Drug Targets 12: 909-921, 2011.
5. Vanden Broeck J, Torfs H, Poels J, et al: Tachykinin-like peptides and their receptors. A review. Ann NY Acad Sci 897: 374-387, 1999.
6. Patacchini R and Maggi CA: Peripheral tachykinin receptors as targets for new drugs. Eur J Pharmacol 429: 13-21, 2001.
7. Rollandy I, Dreux C, Imhoff V and Rossignol B: Importance of the presence of the N-terminal tripeptide of substance P for the stimulation of phosphatidylinositol metabolism in rat parotid gland: a possible activation of phospholipases C and D. Neuropeptides 13: 175-185, 1989.
8. Pradier L, Heuillet E, Hubert JP, et al: Substance P-evoked calcium mobilization and ionic current activation in the human astrocytoma cell line U 373 MG: pharmacological characterization. J Neurochem 61: 1850-1858, 1993.
9. Luo W, Sharif TR and Sharif M: Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res 56: 4983-4991, 1996.
10. DeFea KA, Zalevsky J, Thoma MS, et al: Beta-arrest-independent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol 148: 1267-1281, 2000.
11. Palma C: Tachykinins and their receptors in human malignancies. Curr Drug Targets 7: 1043-1052, 2006.
12. Muñoz M, González-Ortega A and Coveñas R: The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines. Invest New Drugs 30: 529-540, 2012.
13. Muñoz M, Rosso M, Pérez A, et al: The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 39: 427-432, 2005.
14. Muñoz M, Rosso M, Pérez A, et al: Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest Ophthalmol Vis Sci 46: 2567-2570, 2005.
15. Muñoz M, Rosso M and Coveñas R: The NK-1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on human pancreatic cancer cell lines. Lett Drug Des Discov 3: 323-329, 2006.
16. Muñoz M, Rosso M, Aguilar F, et al: NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Invest New Drugs 26: 111-118, 2008.
17. Rosso M, Robles-Frias MJ, Coveñas R, Salinas-Martín MV and Muñoz M: The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumour Biol 29: 245-254, 2008.
18. Muñoz M, Pérez A, Rosso M, et al: The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab Invest 90: 1259-1269, 2010.
19. Navari RM: Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs 16: 1977-1985, 2007.
20. Muñoz M, Rosso M: The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs 28: 187-193, 2010.
21. Quartara L, Altamura M, Evangelista S and Maggi CA: Tachykinin receptor antagonists in clinical trials. Expert Opin Investig Drugs 18: 1843-1864, 2009.
22. Quartara L and Altamura M: Tachykinin receptors antagonists: from research to clinic. Curr Drug Targets 7: 975-992, 2006.
23. Muñoz M, Pérez A, Rosso M, Zamarriego C and Rosso R: Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines. Melanoma Res 14: 183-188, 2004.
24. Muñoz M, Rosso M, Casinello F and Coveñas R: Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence. Breast Cancer Res Treat 122: 601-603, 2010.
25. Muñoz M and Coveñas R: Neurokinin-1 receptor: a new promising target in the treatment of cancer. Discov Med 10: 305-313, 2010.
26. Palma C, Bigioni M, Irrissuto C, et al: Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer 82: 480-487, 2000.
27. Bigioni M, Benzo A, Irrissuto C, Maggi CA and Goso C: Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anticancer Drugs 16: 1083-1089, 2005.
28. Muñoz M, Rosso M, Pérez A, et al: Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138. Invest Ophthalmol Vis Sci 48: 2775-2781, 2007.
29. Ayerza MA, Farfalli GL, Aponte-Tinao L and Muscolo DL: Does increased rate of limb-sparing surgery affect survival in osteosarcoma? Clin Orthop Relat Res 468: 2854-2859, 2010.
30. Weber K, Damron TA, Frassica FJ and Sim FH: Malignant bone tumors. Instr Course Lect 57: 673-688, 2008.
31. Hökfelt T, Pernow B and Wahren J: Substance P: a pioneer amongst neuropeptides. J Intern Med 249: 27-40, 2001.
32. Almendro V, García-Recio S and Gascón P: Tyrosine kinase receptor transactivation associated to G protein-coupled receptors. Curr Drug Targets 11: 1169-1180, 2010.
33. Tattersall FD, Rycroft W, Cumberbatch M, et al: The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 39: 652-663, 2000.